CymaBay Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Wall St futures rise as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins Nobel Physics Prize for Antarctic 'ghost particle' hunt
CymaBay Therapeutics (CBAY) Prices 13M Common Stock Offering at $6.50/Share
July 19, 2017 8:31 AM EDTCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 13,000,000 shares of its common stock at a public offering... More



